18:47 , Feb 15, 2019 |  BC Week In Review  |  Financial News

MacroGenics raises $110M in follow-on

Days after its shares more than doubled based on a Phase III breast cancer readout, MacroGenics Inc. (NASDAQ:MGNX) raised $110 million in a follow-on. MacroGenics sold 5.5 million shares at $20, pricing at a 5%...
18:13 , Feb 13, 2019 |  BC Extra  |  Financial News

MacroGenics raises $110M following breast cancer data

Days after its shares more than doubled based on a Phase III breast cancer readout, MacroGenics Inc. (NASDAQ:MGNX) raised $110 million in a follow-on. MacroGenics sold 5.5 million shares at $20, pricing at a 5%...
13:52 , Jan 29, 2019 |  BC Innovations  |  Distillery Techniques

Drug platforms; other

TECHNOLOGY: Antibody scaffolds; computational models A method of optimizing antibodies for broad activity against different viral strains could be used to generate antibodies to treat infections by influenza and other multi-strain viruses. The method is...
00:44 , Jan 11, 2019 |  BC Extra  |  Preclinical News

UW team builds protein that avoids IL-2 toxicities, forms Neoleukin to develop

University of Washington researchers published a Nature paper Wednesday detailing the construction of a synthetic protein that selectively binds to IL-2 to avoid toxicities that have previously overshadowed interest in the receptor as a therapeutic...
20:44 , Jan 3, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2018

New Therapeutic Targets and Biomarkers: December 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December. Therapeutic targets are defined as any protein, gene or other molecule...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
07:01 , Dec 18, 2018 |  BC Extra  |  Tools & Techniques

Gritstone showcases mass spec-based neoantigen discovery platform

Gritstone Oncology Inc. (NASDAQ:GRTS) unveiled the inner workings of its mass spectrometry-based neoantigen identification platform, EDGE, in a Nature Biotechnology study published Monday. Results from the paper suggest building a machine-learning algorithm based on human...
19:03 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Janssen veterans raise $13M for Centyrin platform

Aro Biotherapeutics Co. (Philadelphia, Pa.) unveiled the lead programs from its Centyrin pipeline on Dec. 11, along with a $13 million seed round from Johnson & Johnson Innovation - JJDC Inc. and BioMotiv LLC (Cleveland,...
16:13 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Obesity Mouse studies identified a secretin analog that could help treat obesity. The compound contains a lactam bridge between two side chains and binds SCTR with higher affinity than secretin. In a mouse model...
12:01 , Dec 11, 2018 |  BC Extra  |  Financial News

Janssen veterans raise $13M for Centyrin platform

Aro Biotherapeutics Co. (Philadelphia, Pa.) unveiled the lead programs from its Centyrin pipeline Tuesday, along with a $13 million seed round from Johnson & Johnson Innovation - JJDC Inc. and BioMotiv LLC (Cleveland, Ohio). Former...